Dr. Perry and Associates Reply

Abstract

Back to table of contents Previous article Next article ArticleNo AccessDr. Perry and Associates ReplyPAUL J. PERRY, DEL D. MILLER, STEPHAN ARNDT, and REMI J. CADORETPAUL J. PERRYSearch for more papers by this author, DEL D. MILLERSearch for more papers by this author, STEPHAN ARNDTSearch for more papers by this author, and REMI J. CADORETSearch for more papers by this authorPublished Online:1 Apr 2006https://doi.org/10.1176/ajp.148.10.1406-bAboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail "Dr. Perry and Associates Reply." American Journal of Psychiatry, 148(10), pp. 1406-b–1407 Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Purchase Save for later Item saved, go to cart PPV Articles - American Journal of Psychiatry $35.00 Add to cart PPV Articles - American Journal of Psychiatry Checkout Please login/register if you wish to pair your device and check access availability. Not a subscriber? Subscribe Now / Learn More PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development. Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.). FiguresReferencesCited byDetailsCited ByLetter to the Editor: Rapid Clozapine Concentration Increase Following Augmentation with Low-Dose Fluvoxamine in 12-Year-Old with Childhood Onset SchizophreniaJournal of Child and Adolescent Psychopharmacology, Vol. 31, No. 7Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations16 October 2021 | Therapeutic Advances in Psychopharmacology, Vol. 11Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients—a genome-wide association study adjusting for smoking habits19 June 2020 | Translational Psychiatry, Vol. 10, No. 1, Vol. 7A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients31 May 2019 | Expert Review of Clinical Pharmacology, Vol. 12, No. 7Treatment of Clozapine Nonresponders23 January 2019 | Current Treatment Options in Psychiatry, Vol. 6, No. 1Clinical Pharmacokinetics of Atypical Antipsychotics: An Update19 June 2018 | Clinical Pharmacokinetics, Vol. 57, No. 12Effect of Valproate and Antidepressant Drugs on Clozapine Metabolism in Patients With Psychotic Mood DisordersTherapeutic Drug Monitoring, Vol. 40, No. 4Psychosis: Schizophrenia and Related Disorders25 January 2018Expert Opinion on Pharmacotherapy, Vol. 18, No. 4Cigarette smoking has a differential effect on the plasma level of clozapine in Taiwanese schizophrenic patients associated with the CYP1A2 gene −163A/C single nucleotide polymorphismPsychiatric Genetics, Vol. 26, No. 4BMC Psychiatry, Vol. 15, No. 1Psychopharmacology, Vol. 225, No. 3The Psychopharmacology Algorithm Project at the Harvard South Shore ProgramHarvard Review of Psychiatry, Vol. 21, No. 1Therapeutic Drug Monitoring of Common AntipsychoticsTherapeutic Drug Monitoring, Vol. 34, No. 6Association Study of 27 Annotated Genes for Clozapine PharmacogeneticsJournal of Clinical Psychopharmacology, Vol. 32, No. 4Annales de Toxicologie Analytique, Vol. 24, No. 3The World Journal of Biological Psychiatry, Vol. 13, No. 5Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy23 February 2011 | Neuropsychopharmacology, Vol. 36, No. 6Clozapine and Global Cognition in SchizophreniaJournal of Clinical Psychopharmacology, Vol. 30, No. 4, Vol. 120Neuropsychopharmacology, Vol. 35, No. 11Therapeutic Drug Monitoring, Vol. 32, No. 5Clozapine Exposure and the Impact of Smoking and Gender: A Population Pharmacokinetic StudyTherapeutic Drug Monitoring, Vol. 31, No. 3Journal of Clinical Psychopharmacology, Vol. 29, No. 4Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients28 February 2008 | Journal of Psychopharmacology, Vol. 22, No. 8European Journal of Clinical Pharmacology, Vol. 64, No. 2Expert Opinion on Pharmacotherapy, Vol. 9, No. 3Therapeutic Drug Monitoring-Based Clozapine Dosing RecommendationsTherapeutic Drug Monitoring, Vol. 29, No. 1Statistics in Medicine, Vol. 26, No. 9Journal of Neural Transmission, Vol. 114, No. 11Journal of Chromatography B, Vol. 846, No. 1-2Neuropsychopharmacology, Vol. 32, No. 7Therapeutic Drug Monitoring, Vol. 29, No. 5International Clinical Psychopharmacology, Vol. 22, No. 4British Journal of Clinical Pharmacology, Vol. 64, No. 1Acta Pharmacologica Sinica, Vol. 28, No. 7Clinical Pharmacokinetics, Vol. 46, No. 5European Archives of Psychiatry and Clinical Neuroscience, Vol. 256, No. 6Journal of Psychiatric Intensive Care, Vol. 2, No. 02Neuropsychopharmacology, Vol. 31, No. 5Clinical Neuropharmacology, Vol. 29, No. 1Therapeutic Drug Monitoring, Vol. 28, No. 5Expert Opinion on Therapeutic Targets, Vol. 10, No. 4Psychopharmacology, Vol. 179, No. 2European Archives of Psychiatry and Clinical Neuroscience, Vol. 255, No. 4International Clinical Psychopharmacology, Vol. 20, No. 3Journal of Psychiatric Practice, Vol. 11, No. 5Case Studies of Adjunctive Agents in Clozapine-Resistant Schizophrenic PatientsClinical Neuropharmacology, Vol. 28, No. 1CNS Drugs, Vol. 19, No. 10A Positron Emission Tomography Study of the 5-Ht1A Receptor in Schizophrenia and during Clozapine Treatment2 July 2016 | Journal of Psychopharmacology, Vol. 18, No. 3Nonresponse to Clozapine and Ultrarapid CYP1A2 ActivityJournal of Clinical Psychopharmacology, Vol. 24, No. 2Psychopharmacology, Vol. 177, No. 1-2, Vol. 5Predictors of Clinical Outcome in Schizophrenic Patients Responding to ClozapineJournal of Clinical Psychopharmacology, Vol. 23, No. 6Clinical Pharmacokinetics, Vol. 42, No. 7Optimizing dosing in atypical neuroleptic monotherapy1 April 2022 | Dialogues in Clinical Neuroscience, Vol. 4, No. 4Journal of Clinical Psychopharmacology, Vol. 22, No. 6Therapeutic Drug Monitoring, Vol. 24, No. 5LaboratoriumsMedizin, Vol. 26, No. 1/2Expert Review of Neurotherapeutics, Vol. 2, No. 1Comment: Unanticipated Plasma Concentrations in Two Clozapine-Treated Patients28 June 2016 | Annals of Pharmacotherapy, Vol. 35, No. 12Unanticipated Plasma Concentrations in Two Clozapine-Treated Patients12 December 2016 | Annals of Pharmacotherapy, Vol. 35, No. 9Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 755, No. 1-2Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 759, No. 1Journal of Clinical Psychopharmacology, Vol. 21, No. 1Journal of Clinical Psychopharmacology, Vol. 21, No. 3Journal of Clinical Psychopharmacology, Vol. 21, No. 4Clozapine pharmacokinetics and pharmacodynamics studied with CYP1A2-null mice2 July 2016 | Journal of Psychopharmacology, Vol. 14, No. 4Chromatographia, Vol. 51, No. 3-4CNS Drugs, Vol. 13, No. 3Clinical Drug Investigation, Vol. 19, No. 4Paediatric Drugs, Vol. 2, No. 4Risperidone and Clozapine for Treatment-Resistant SchizophreniaEDUARDO DUNAYEVICH, M.D., , and ANJAN CHATTERJEE, M.D., 1 July 1999 | American Journal of Psychiatry, Vol. 156, No. 7Bedeutung des therapeutischen Drug-Monitoring im Rahmen der Rezidivprophylaxe mit ClozapinChromatographia, Vol. 49, No. 1-2Journal of Clinical Psychopharmacology, Vol. 19, No. 2Journal of Clinical Psychopharmacology, Vol. 19, No. 2Therapeutic Drug Monitoring, Vol. 21, No. 3The Clinical Use of Plasma Clozapine Levels26 June 2016 | Australian & New Zealand Journal of Psychiatry, Vol. 32, No. 4Risperidone Versus Clozapine in Treatment-Resistant Chronic Schizophrenia: A Randomized Double-Blind StudyG. Bondolfi, M.D., H. Dufour, M.D., M. Patris, M.D., J. P. May, M.D., U. Billeter, M.D., C. B. Eap, Ph.D., and P. Baumann, Ph.D., on Behalf of the Risperidone Study Group1 April 1998 | American Journal of Psychiatry, Vol. 155, No. 4The Partial Responder to Antipsychotic Medications: Putting the Pieces together29 June 2016 | Journal of the American Psychiatric Nurses Association, Vol. 4, No. 1Archives of General Psychiatry, Vol. 55, No. 1Human Psychopharmacology: Clinical and Experimental, Vol. 13, No. 5Chromatographia, Vol. 47, No. 1-2Nordic Journal of Psychiatry, Vol. 51, No. sup40Journal of Clinical Psychopharmacology, Vol. 18, No. 4Journal of Clinical Psychopharmacology, Vol. 18, No. 6Journal of Pharmaceutical and Biomedical Analysis, Vol. 16, No. 2Journal of Clinical Psychopharmacology, Vol. 17, No. 6Therapeutic Drug Monitoring, Vol. 19, No. 2Therapeutic Drug Monitoring, Vol. 19, No. 4Predictors of Response to ClozapinePsychiatric Annals, Vol. 26, No. 7Polymorphic Variation at Neurotransmitter Receptor Loci and Clinical ResponsePsychiatric Annals, Vol. 26, No. 7Plasma Antipsychotic Drug Concentrations: Practical Clinical Considerations30 June 2016 | Journal of Pharmacy Practice, Vol. 9, No. 2Psychopharmacology, Vol. 124, No. 1-2Psychopharmacology, Vol. 124, No. 1-2Psychiatric Quarterly, Vol. 67, No. 4Neurochemical Research, Vol. 21, No. 12Journal of Pharmaceutical and Biomedical Analysis, Vol. 14, No. 11Journal of Clinical Psychopharmacology, Vol. 16, No. 1Journal of Clinical Psychopharmacology, Vol. 16, No. 2Therapeutic Drug Monitoring, Vol. 18, No. 2Therapeutic Drug Monitoring, Vol. 18, No. 6Psychiatry and Clinical Neurosciences, Vol. 50, No. 5Nordic Journal of Psychiatry, Vol. 50, No. 5Thermal degradation of clozapine-N-oxide to clozapine during gas chromatographic analysisJournal of Chromatography B: Biomedical Sciences and Applications, Vol. 668, No. 1Biomedical Chromatography, Vol. 9, No. 1Psychopharmacology, Vol. 117, No. 3Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 673, No. 2Journal of Clinical Psychopharmacology, Vol. 15, No. 2Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 622, No. 1Clozapine in the Treatment of Refractory Schizophrenia: Canadian Policies and Clinical Guidelines *1 September 1992 | The Canadian Journal of Psychiatry, Vol. 37, No. 7La clozapine dans le traitement de la schizophrénie réfractaire: règles et directives canadiennes *1 September 1992 | The Canadian Journal of Psychiatry, Vol. 37, No. 7Clozapine concentrations and clinical response in schizophrenic patients1 April 2006 | American Journal of Psychiatry, Vol. 149, No. 8Identification of Mood Variance in DepressionREX WILLIAM COWDRY1 April 2006 | American Journal of Psychiatry, Vol. 149, No. 8Dr. Hall and Associates ReplyDONALD P. HALLJR., HELEN C. SING, and ALAN J. ROMANOSKI1 April 2006 | American Journal of Psychiatry, Vol. 149, No. 8Regarding the Use and Accuracy of the Family History MethodEWALD HORWATH1 April 2006 | American Journal of Psychiatry, Vol. 149, No. 8Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 583, No. 2 Volume 148Issue 10 October 1991Pages 1406-b-1407 Metrics PDF download History Published online 1 April 2006 Published in print 1 October 1991